CURE Media Group’s flagship product will be hosting its monthly Tweet Chat on Tuesday, April 10, at 1 p.m. ET, to ask questions and facilitate discussions about its most recent specialty issue on gastrointestinal (GI) cancer.
“We look forward to hosting the next edition of the #CureConnect Tweet Chat on April 10 and listening to stories and having discussions about GI cancer and its treatment,” said Michael J. Hennessy Jr., president of MJH Associates, parent company of CURE Media Group.
CURE® welcomes all patients and their loved ones, as well as health care professionals, advocates and nonprofit organizations to join using the hashtag #CureConnect. Highlights to be discussed from the special issue:
- High Expectations: Immunotherapy may play a growing role in treating GI cancers categorized as MSI-high;
- A Cut Above: Laparoscopy proves safer than open surgery and costs less than robotic resection for colorectal cancer;
- A Major Turnaround: After 10 years without a new drug for liver cancer, two approvals and a promising pipeline are changing the landscape;
- Beneath the Surface: Progress in cholangiocarcinoma treatment was long stalled, but now scientists are identifying genetic drivers likely to respond to novel drugs.
For more information, visit curetoday.com, or find us on Twitter @cure_magazine or on Facebook @curemagazine.
About CURE®:
CURE Media Group is the leading resource for cancer updates, research and education. It combines a full suite of media products, including its industry-leading website, CUREtoday.com; innovative video programs, such as CURE Connections®; a series of widely attended live events; and CURE® magazine, which reaches over 1 million readers. CURE Media Group is part of the Cranbury, New Jersey-based MJH Associates family of businesses, which includes the acclaimed OncLive® (http://www.onclive.com) platform of resources for the practicing oncologist. For more information, visit http://www.curetoday.com or http://www.mjhassoc.com.
